

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA223; Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease**

This guidance was issued May 2011 with a review date of May 2014.

**Background**

At the GE meeting of 6 May 2014 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	The guidance should be transferred to the 'static guidance list'.
<b>Rationale for selecting this proposal</b>	No changes to the marketing authorisation, drug prices or the evidence have been identified that would lead to a change in the recommendations of the original guidance. No ongoing studies have been identified that would satisfy the research recommendation in the guidance. It is therefore proposed that the guidance is placed on the static list.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	The guidance should be transferred to the 'static guidance list'.
--	---

Respondent	Response to proposal	Details <sup>1</sup>	Comment from Technology Appraisals
Society of Vascular Nurses	Agree	Following consultation with the SVN committee members we are happy to support the transfer of this guidance to the 'static guidance list'.	Comment noted.
Vascular Society of Great Britain and Ireland	Agree	The Vascular Society is in agreement for this topic to be moved to the static list.	Comment noted

**No response received from:**

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Actavis (naftidrofuryl oxalate)</li> <li>• Genus Pharmaceuticals (inositol nicotinate)</li> <li>• Merck Serono (naftidrofuryl oxalate)</li> <li>• Otsuka (cilostazol)</li> <li>• Sanofi (pentoxifylline)</li> <li>• Teva (cilostazol, naftidrofuryl oxalate)</li> </ul> <p><u>Patient/carer groups</u></p>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> </ul>
--	---

<sup>1</sup> Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

- Afiya Trust
- AntiCoagulation Europe
- Black Health Agency
- Blood Pressure UK
- Equalities National Council
- HEART UK
- Lifeblood: The Thrombosis Charity
- Muslim Council of Britain
- Muslim Health Network
- South Asian Health Foundation
- Specialised Healthcare Alliance

#### Professional groups

- Association of Anaesthetists
- Association of Surgeons of Great Britain and Ireland
- British Association for Nursing in Cardiovascular Care
- British Atherosclerosis Society
- British Cardiovascular Intervention Society (BCIS)
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Society of Cardiovascular Imaging
- British Society of Interventional Radiology
- British Vein Institute
- Chartered Society of Physiotherapy
- The Radiological Research Trust
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists

- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium

#### Comparator manufacturers

- None

#### Relevant research groups

- Antithrombotic Trialists' Collaboration
- Cochrane Heart Group
- Cochrane Peripheral Vascular Diseases Group
- Health Research Authority
- MRC Clinical Trials Unit
- National Institute for Health Research
- Research Institute for the Care of Older People
- Wellcome Trust

#### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### Associated Guideline Groups

- National Clinical Guideline Centre

#### Associated Public Health Groups

<ul style="list-style-type: none"> <li>• Royal College of Radiologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• Society for Vascular Technology</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• UK Health Forum</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Hambleton, Richmondshire and Whitby CCG</li> <li>• NHS North Tyneside CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>
--	--

**GE paper sign-off:** Elisabeth George, Associate Director – Technology Appraisals Programme

**Contributors to this paper:**

Technical Lead: Christian Griffiths

Project Manager: Andrew Kenyon

23 June 2014